Research Summary: The following information is provided for research context only.
Retatrutide is a synthetic triple-receptor agonist peptide that binds three incretin and glucagon receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. Each receptor mediates a distinct signaling pathway within in-vitro metabolic and endocrine research models.
Because it engages all three receptors at once, retatrutide provides researchers with a reference tool for studying combined receptor activation that single- or dual-agonist compounds cannot replicate. Reported areas of laboratory interest include receptor-binding affinity, downstream cAMP signaling, incretin pathway crosstalk, and comparative agonist studies.
As the most recently characterized compound in the GLP-1 agonist research class, retatrutide is used as a frontier reference compound in in-vitro metabolic pathway research.
This vial contains lyophilized Retatrutide at high purity, verified by independent, third-party analytical testing.
Structure, CAS and molecular data, receptor pharmacology, storage and published literature: see our Retatrutide research reference.
Reviews
There are no reviews yet.